-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH Poster Walk on Diversity, Equity, and Inclusion in Hematologic Malignancies and Cellular Therapy

Program: ASH Poster Walks
Hematology Disease Topics & Pathways:
Biological therapies, Research, Bone Marrow Failure Syndromes, Clinical Practice (Health Services and Quality), Workforce, Clinical Research, GVHD, Diversity, Equity, and Inclusion (DEI) , Immune Disorders, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Human, Study Population
Wednesday, December 14, 2022: 5:00 PM-6:00 PM
(VIRTUAL PROGRAM)
Although outcomes of various hematologic malignancies are improving, disparities continue to impact patients’ access to and outcomes following care. This poster walk will highlight work being done to investigate and address factors which impact the provision of care across malignant hematology for patients from different racial and ethnic backgrounds, those of lower socio-economic status, and other vulnerable groups.

The walk will also feature work being done to make the field more inclusive for patients, institutions, and practitioners. Review of this research will improve the audiences' understanding of disparities in malignant hematology and cellular therapy, which is necessary to identify specific patient groups at risk for compromised care. This information is a pre-requisite to enhance outcomes and care delivery.

Lastly, the walk will serve to connect stakeholders interested in Diversity, Equity, and Inclusion (DEI) in malignant hematology and cellular therapy and will facilitate discussions on the state of DEI research in the field. There will be a discussion on how such efforts can support critically important work to diversify patient populations, mitigate barriers to care, and maximize the equitable provision of optimal care for less or under-privileged groups. 

Lama Sawalha, MD1*, Ghulam Rehman Mohyuddin, MD2, Aaron M Goodman3, Nico Gagelmann4*, Amar H Kelkar, MD5 and Samer Al Hadidi, MD, MSc6

1Hashemite University, Amman, Jordan
2Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT
3University of California San Diego Moores Cancer Center, San Diego, CA
4University Medical Center Hamburg-Eppendorf, Department of Stem Cell Transplantation, Hamburg, Germany
5Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
6Myeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR

Adam J. de Smith, PhD1, Lara Wahlster, MD, PhD2*, Soyoung Jeon, BSc1*, Fulong Yu, PhD2*, Susan Black2*, Steven Gazal, PhD1*, Nicholas Mancuso, PhD1*, Catherine Metayer, MD, PhD3*, Xiaomei Ma, PhD4*, Joseph L. Wiemels, PhD1*, Charleston W. K. Chiang, PhD1* and Vijay G. Sankaran, MD, PhD2

1Center for Genetic Epidemiology, Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA
2Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
3School of Public Health, University of California Berkeley, Berkeley, CA
4Department of Chronic Disease Epidemiology, Yale University School of Public Health, New Haven, CT

Kara I. Cicero, MD, MPH1, Alfred I. Neugut, MD, PhD2*, Andrew H. Doyle3*, Divaya Bhutani, MD4, Amer Assal, MD5, Ran Reshef, MD, MSc6, Markus Y. Mapara, MD7, Suzanne Lentzsch, MD, PhD8 and Rajshekhar Chakraborty, MBBS9

1New York Presbyterian, Columbia University Medical Center, New York, NY
2Columbia University Medical Center, New York
3Columbia University, New York, NY
4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
5Blood and Marrow Transplantation Program, Columbia University Medical Center, New York, NY
6Blood and Marrow Transplantation Program, Columbia University, New York, NY
7Department of Medicine, Division of Hematology/Oncology, Columbia University College of Physcians and Surgeons, New York, NY
8Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY
9Hematology and Oncology, Columbia University Medical Center, New York, NY

Erik Wu1*, Alexander V Stanisic, BS1*, David J. Fei-Zhang, BA1*, Marquita Lewis-Thames, MS, MPH, PhD2,3* and Sherif M. Badawy, MD1,4

1Northwestern University Feinberg School of Medicine, Chicago, IL
2Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
3Center for Community Health, Northwestern University Feinberg School of Medicine, Chicago, IL
4Ann %26 Robert Lurie Children's Hospital, Chicago, IL

Oluwasegun Akinyemi, MD1,2*, Faith O Abodunrin, MD3, Oluwatayo Adeoye, MD4*, Akinwale Akingbule, MD, MS5*, Olanrewaju Oni, MD, MS6*, Bolarinwa Akinwumi, MD, MS7*, Ademola Ojo, MD8*, Oluwaseun B Ogunbona, MBBS PhD9* and Peter Silberstein, MD10*

1The Clive O. Callender Outcomes Research Center, Howard University College of Medicine, Macomb, IL
2Department of Health Policy and Management, University of Maryland School of Public Health, College Park, MD
3Department of Internal Medicine, Creighton University, OMAHA, NE
4Department of Internal Medicine, St Elizabeth's Medical Center, Boston, MA
5Department of Public Health, Ozark valley medical Clinic,, Branson, MO
6Department of Pathology, Howard University College of Medicine, Washington, DC
7Western Illinois University, Macomb, IL
8Department of Internal Medicine, Howard University College of Medicine, Washington, DC
9Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX
10Department of Medicine, Creighton University Medical Center, Omaha, NE

Reem Karmali, MD, MSc1, Narendranath Epperla, MD, MS2, Geoffrey Shouse, PhD, DO3, Jason T. Romancik, MD4, Tamara K. Moyo, MD, PhD5*, Vaishalee P. Kenkre, MD6, Thomas A. Ollila, MD7, Lindsey A. Fitzgerald, MD8, Brian T. Hess, MD9, Andrew M. Evens, DO, MBA, MMSc10, Ishan Roy11*, Joanna Zurko, MD12, Sayan Mullick Chowdhury, DO, PhD13*, Kaitlin Annunzio, DO14, Robert Ferdman, MD15*, Rahul Bhansali, MD16*, Elyse I. Harris, MD17, McKenzie Sorrell, DO9, Jieqi Liu, MD18, Imran A. Nizamuddin, MD19, Shuo Ma, MD20, Jonathan Moreira, MD21, Jane N. Winter, MD22, Barbara Pro, MD22,23, Deborah M. Stephens, DO24, Alexey V Danilov, MD25, Nirav N. Shah, MD26, Jonathon B. Cohen, MD, MS27, Stefan K. Barta, MD28, Pallawi Torka, MD15 and Leo I. Gordon, MD21

1Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL
2The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH
3Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA
4Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA
5Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
6Carbone Cancer Center, University of Wisconsin, Madison, WI
7Lifespan Cancer Institute, Brown University, Providence, RI
8Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
9Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
10Rutgers Cancer Institute of New Jersey, Warren, NJ
11Northwestern University, Chicago, IL
12University of Wisconsin, Madison, WI
13Ohio State University Medical Center, Columbus, OH
14The Ohio State University, Columbus, OH
15Roswell Park Comprehensive Cancer Center, Buffalo, NY
16Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
17Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI
18Rutgers Cancer Institute of New Jersey, Hoboken, NJ
19Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
20Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL
21Department of Medicine, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL
22Division of Hematology and Oncology, Northwestern University, Chicago, IL
23Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
24Huntsman Cancer Institute, Salt Lake City, UT
25Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
26Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, WI
27Department of Hematology and Medical Oncology, Emory University, Atlanta, GA
28Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

See more of: ASH Poster Walks